Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06083857 · ClinicalTrials.gov registry record · Phase 1
PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer
A Phase 1 study of Non-Small Cell Lung Cancer, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
- 1
- Study location
NCT06083857: Active Phase 1 study of Non-Small Cell Lung Cancer, sponsored by M.D. Anderson Cancer Center.
NCT06083857 is a Phase 1 study of Non-Small Cell Lung Cancer that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 3 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06083857, a Phase 1 study of Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn if the combination of amivantamab and tepotinib can help to control NSCLC. The safety of this drug combination will also be studied.
Conditions Studied
Interventions
- DRUG Amivantamab
- DRUG Tepotinib
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2024-06-18 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
What the registry record for NCT06083857 still lists
NCT06083857 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Amivantamab is the first listed.
NCT06083857 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06083857 about?
NCT06083857 is a clinical study titled "PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer". To learn if the combination of amivantamab and tepotinib can help to control NSCLC. The safety of this drug combination will also be studied.
What is the current status of trial NCT06083857?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2024-06-18. Estimated completion is 2027-12-31.
What conditions does trial NCT06083857 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT06083857?
The interventions under investigation include: Amivantamab (DRUG), Tepotinib (DRUG).
Who is sponsoring clinical trial NCT06083857?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06083857 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06083857's enrollment target sits among peer trials
3 455th of 454 the lowest of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI